Trial · NCT01636843
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
NCT01636843, Phase 2, Terminated, Novo Nordisk A/S
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate. Trials, record NCT01636843. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01636843
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
- NCT number
- NCT01636843
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 298 participants, actual
- Lead sponsor
- Novo Nordisk A/S
- Conditions
- Inflammation, Rheumatoid Arthritis
- Interventions
- NNC0109-0012, placebo
- First posted
- 2012-07-10
- Last updated
- 2018-09-05
- Other registries' IDs
- eudract:2012-000610-11
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | ACR20 (defined as 20% improvement in American College of Rheumatology criteria measures) | At week 12 (responder or non-responder) | |
| Secondary | ACR20, ACR50 and ACR70 improvement of ACR score from baseline | At weeks 12 and 24 | |
| Secondary | Change in DAS28-CRP (defined as Disease Activity Score for 28 joints with C-reactive protein measure) from baseline | At weeks 12 and 24 | |
| Secondary | Simplified Disease Activity Index (SDAI) remission (SDAI of 3.3 or below) | At weeks 12 and 24 | |
| Secondary | European League Against Rheumatism (EULAR) criteria response | At weeks 12 and 24 | |
| Secondary | Change from baseline in the overall scores of Short Form Health Survey (SF-36v2) | At weeks 12 and 24 | |
| Secondary | Change from baseline in the overall scores of Health Assessment Questionnaire - Disability Index (HAQ-DI) | At weeks 12 and 24 | |
| Secondary | Incidence and type of adverse events (AEs) | At weeks 12 and 24 | |
| Secondary | Change from baseline in van der Heijde modified Sharp score | At weeks 12 and 24 | |
| Secondary | ACR20/50/70 (20%, 50% or 70% improvement of ACR (American College of Rheumatology) score from baseline) | Week 52 |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01636843
GET https://conductscience.org/api/trials/v1/NCT01636843/registered